Evidence – Using CRISPR Screening to Decode Tumour Microenvironment Biology & Identify Next Generation Immunotherapy Targets

4:00 pm - Wednesday 2nd December 2026

  • Applying CRISPR-based approaches to uncover mechanisms of immune suppression within the tumour microenvironment
  • Leveraging advanced tumour models to identify and validate novel immuno-oncology targets
  • Using translationally relevant systems to prioritise targets with the greatest potential to drive durable anti-tumour responses

Speakers:

Associate Director
AstraZeneca